NCT04956484View on ClinicalTrials.gov

Belimumab In Early Systemic Lupus Erythematosus

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 8, 2022

Study Completion Date

April 8, 2022

Conditions
Lupus Erythematosus, Systemic
Interventions
BIOLOGICAL

Belimumab

Belimumab 10 mg/kg

DRUG

Standard of care

Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.

Trial Locations (1)

100730

Peking Union Medical College hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04956484 - Belimumab In Early Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter